Century Therapeutics Inc (IPSC) Stock Price, Quote & News

Company Profile

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 a...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 817 5790

Website: www.centurytx.com

Address:

25 North 38th Street, 11th Floor, Philadelphia, United States

Beanie_Mojo May. 13 at 3:58 PM

$IPSC

0 · Reply

Beanie_Mojo May. 13 at 3:04 PM

$IPSC pop news! 🗞️ only way ⬆️

0 · Reply

Jnutz14 May. 13 at 12:21 PM

$IPSC Good earnings. Now release the trial results!!!

0 · Reply

Beanie_Mojo May. 12 at 1:40 PM

$IPSC let's GO !?!

0 · Reply

Beanie_Mojo May. 11 at 3:47 PM

$IPSC it seems. its stuck on 2.30$ range. back to pre historic crap. until updated news

0 · Reply

Beanie_Mojo May. 7 at 1:10 PM

$IPSC added the dip, - avg. down - to + gains 💲💲 lfg. 🚀

0 · Reply

Beanie_Mojo May. 5 at 1:33 PM

$IPSC ▶️ 2.50$ restesting.

0 · Reply

Beanie_Mojo May. 4 at 1:34 PM

$IPSC

0 · Reply

cta7978 May. 4 at 2:20 AM

$FATE FATE trades at a depressed 0.86 P/B with BVPS ~$1.80 and stock ~$1.53. Peers $IPSC (2.5x P/B) and $SANA (~5.5x P/B) suggest a rerate to $4.50–$9.90/share (or higher) at similar multiples. FATE is further ahead clinically with Phase 1 FT819 CAR-T data in autoimmune (SLE etc.) showing meaningful responses, while IPSC and SANA remain mostly pre-IND or earlier in comparable programs. Strong data could easily justify a 4–7x+ P/B premium given the iPSC leadership and de-risking. High risk/high reward—watch the next readouts. DYOR.

1 · Reply

PaulLaurent May. 1 at 2:24 PM

Thanks $SOBR ! - Done for the day! $SOBR $IPSC $AKAN $SKLZ $CUE

0 · Reply

Century Therapeutics Reports First Quarter Financial Results and Business Updates

Apr 30, 2026, 4:05 PM EDT - 12 days ago

Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions

2026-04-21T10:29:09.000Z - 22 days ago

Century Therapeutics price target raised to $5 from $2 at H.C. Wainwright

2026-03-12T12:07:51.000Z - 2 months ago

Century Therapeutics reports FY25 EPS (14c), consensus (17c)

Mar 10, 2026, 4:20 PM EDT - 2 months ago

Century Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 4, 2026, 9:50 AM EST - 2 months ago

Century Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:00 AM EST - 2 months ago

Century Therapeutics to Participate in Upcoming Investor Conferences in March

2026-02-25T10:35:26.000Z - 2 months ago

Century Therapeutics initiated with a Buy at TD Cowen

Feb 16, 2026, 1:00 PM EST - 3 months ago

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

FATE

2026-02-05T21:20:27.000Z - 3 months ago

Century Therapeutics files to sell 176.09M shares of common stock for holders

2026-01-20T11:56:32.000Z - 4 months ago

Century Therapeutics price target raised to $4 from $2 at Piper Sandler

2026-01-08T16:45:33.000Z - 4 months ago

Century Therapeutics price target lowered to $6.60 from $8 at Clear Street

2026-01-08T13:35:27.000Z - 4 months ago

Century Therapeutics prices 117.4M shares at $1.15 in private placement

2025-12-09T13:10:18.000Z - 5 months ago

Century Therapeutics appoints Lee, Murphy to board of directors

Dec 3, 2025, 10:00 AM EST - 5 months ago

Century Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 4:01 PM EST - 6 months ago

Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

2025-11-17T11:25:10.000Z - 6 months ago

Century Therapeutics downgraded to Market Perform from Outperform at Leerink

2025-11-13T12:36:04.000Z - 6 months ago

Century Therapeutics reports Q3 EPS (40c) vs (37c) last year

Nov 13, 2025, 7:30 AM EST - 6 months ago

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-11-13T12:21:46.000Z - 6 months ago

Century Therapeutics announces new beta islet program for Type 1 diabetes

Nov 13, 2025, 7:00 AM EST - 6 months ago

Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

Oct 21, 2025, 12:20 PM EDT - 7 months ago

Century Therapeutics Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Oct 14, 2025, 4:01 PM EDT - 7 months ago

Century Therapeutics to Present at Chardan's 9th Annual Genetic Medicines Conference

Sep 5, 2025, 7:00 AM EDT - 8 months ago

Century Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 22, 2025, 8:00 AM EDT - 9 months ago

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:01 PM EDT - 9 months ago

Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

2025-07-10T20:55:08.000Z - 10 months ago

Century Therapeutics files $200M mixed securities shelf

May 28, 2025, 4:01 PM EDT - 1 year ago

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

May 15, 2025, 4:01 PM EDT - 1 year ago

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

Apr 22, 2025, 10:00 AM EDT - 1 year ago

Century Therapeutics Transcript: Status Update

2025-04-03T10:16:15.000Z - 1 year ago

Century Therapeutics price target lowered to $2 from $5 at H.C. Wainwright

2025-03-24T12:00:36.000Z - 1 year ago

Century Therapeutics price target lowered to $7 from $11 at Chardan

2025-03-21T12:25:26.000Z - 1 year ago

Century Therapeutics price target lowered to $5 from $12 at Guggenheim

2025-03-20T10:46:31.000Z - 1 year ago

Century Therapeutics price target lowered to $2 from $4 at Piper Sandler

2025-03-19T20:30:09.000Z - 1 year ago

Century Therapeutics trading resumes

2025-03-19T20:06:39.000Z - 1 year ago

Century Therapeutics trading halted, news pending

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

2025-01-21T12:20:15.000Z - 1 year ago

Century announces investigator-initiated Phase 1/2 trial of CNTY-101

2024-12-30T11:25:14.000Z - 1 year ago

Century Therapeutics price target lowered to $4 from $12 at Piper Sandler

BMY

Dec 4, 2024, 3:00 PM EST - 1 year ago

Century Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 9:30 AM EST - 1 year ago

Century Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 5, 2024, 9:05 AM EST - 1 year ago

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 4, 2024, 7:00 AM EST - 1 year ago

Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jun 3, 2024, 7:00 AM EDT - 2 years ago

Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting

May 9, 2024, 7:30 AM EDT - 2 years ago

Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Apr 23, 2024, 7:00 AM EDT - 2 years ago

Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Apr 11, 2024, 7:00 AM EDT - 2 years ago

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

Apr 8, 2024, 4:05 PM EDT - 2 years ago

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 26, 2024, 1:30 PM EDT - 2 years ago

Century Therapeutics Transcript: H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 19, 2024, 7:00 AM EDT - 2 years ago

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 14, 2024, 7:30 AM EDT - 2 years ago

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

Mar 5, 2024, 6:03 PM EST - 2 years ago

Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Feb 1, 2024, 7:00 AM EST - 2 years ago

Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 9, 2023, 12:00 PM EST - 2 years ago

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

Dec 6, 2023, 7:30 AM EST - 2 years ago

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

$Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus$

Dec 6, 2023, 7:30 AM EST - 2 years ago

Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

Nov 21, 2023, 7:00 AM EST - 2 years ago

Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 9, 2023, 7:01 AM EST - 2 years ago

Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 7:00 AM EST - 2 years ago

Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases

Sep 26, 2023, 7:00 AM EDT - 2 years ago

Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

Aug 9, 2023, 7:30 AM EDT - 3 years ago

Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

May 11, 2023, 7:30 AM EDT - 3 years ago

Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

Apr 17, 2023, 7:00 AM EDT - 3 years ago

Century Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit

Apr 12, 2023, 8:30 AM EDT - 3 years ago

Century Therapeutics Announces Leadership Changes

Mar 16, 2023, 7:30 AM EDT - 3 years ago

Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates

Mar 15, 2023, 4:01 PM EDT - 3 years ago

Century Therapeutics to Present at the AACR Annual Meeting 2023

Feb 21, 2023, 7:00 AM EST - 3 years ago

Century Therapeutics to Present at Upcoming Investor Conferences

$Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas$

Feb 8, 2023, 7:30 AM EST - 3 years ago

Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas

Jan 9, 2023, 9:06 PM EST - 3 years ago

Century Therapeutics closes its Seattle hub amid wider cuts, departure of R&D head

Jan 5, 2023, 4:01 PM EST - 3 years ago

Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026

Jan 4, 2023, 7:00 AM EST - 3 years ago

Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 22, 2022, 7:00 AM EST - 3 years ago

Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 11, 2022, 7:00 AM EST - 3 years ago

Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates

Nov 10, 2022, 7:30 AM EST - 3 years ago

Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

Nov 2, 2022, 7:05 AM EDT - 3 years ago

Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022

Beanie_Mojo May. 13 at 3:58 PM

$IPSC

0 · Reply

Beanie_Mojo May. 13 at 3:04 PM

$IPSC pop news! 🗞️ only way ⬆️

0 · Reply

Jnutz14 May. 13 at 12:21 PM

$IPSC Good earnings. Now release the trial results!!!

0 · Reply

Beanie_Mojo May. 12 at 1:40 PM

$IPSC let's GO !?!

0 · Reply

Beanie_Mojo May. 11 at 3:47 PM

$IPSC it seems. its stuck on 2.30$ range. back to pre historic crap. until updated news

0 · Reply

Beanie_Mojo May. 7 at 1:10 PM

$IPSC added the dip, - avg. down - to + gains 💲💲 lfg. 🚀

0 · Reply

Beanie_Mojo May. 5 at 1:33 PM

$IPSC ▶️ 2.50$ restesting.

0 · Reply

Beanie_Mojo May. 4 at 1:34 PM

$IPSC

0 · Reply

cta7978 May. 4 at 2:20 AM

1 · Reply

PaulLaurent May. 1 at 2:24 PM

Thanks $SOBR ! - Done for the day! $SOBR $IPSC $AKAN $SKLZ $CUE

0 · Reply

Jnutz14 May. 1 at 2:18 PM

$IPSC

0 · Reply

Beanie_Mojo May. 1 at 1:59 PM

$IPSC

0 · Reply

PaulLaurent May. 1 at 6:23 AM

🌅 4:00am EST Watchlist — May 1, 2026 $SOBR – Proposed business combination with Clean World Ventures, shifting the story toward zero-carbon green energy tech manufacturing. Major strategic pivot/merger catalyst, but traders are watching dilution, approval risk, reverse-split risk, and Nasdaq compliance. $IPSC – Selected for an oral presentation of CNTY-813 preclinical data at ADA’s 86th Scientific Sessions. Visibility/pipeline catalyst tied to type 1 diabetes, cell therapy, and iPSC-derived treatment momentum, with IND still targeted for 4Q 2026. Potential multi-day runners: $AKAN ✅ $SKLZ ✅ $CUE ✅

1 · Reply

AlertsAndNews Apr. 30 at 11:07 PM

$IPSC closing pretty well here in after hours close

0 · Reply

Beanie_Mojo Apr. 30 at 3:41 PM

$IPSC 🌎 Long ways to go .... 🌙

0 · Reply

biopuzzle Apr. 28 at 7:24 PM

$IPSC H&S on 6 mos. watching

1 · Reply

Beanie_Mojo Apr. 27 at 2:43 PM

$IPSC

0 · Reply

Beanie_Mojo Apr. 27 at 12:56 PM

$IPSC Green field on its way

0 · Reply

Beanie_Mojo Apr. 24 at 2:16 PM

$IPSC enough with rat chews - let it reverse back to green.

0 · Reply

Beanie_Mojo Apr. 23 at 1:37 PM

$IPSC 💹

0 · Reply

Beanie_Mojo Apr. 22 at 8:24 PM

$IPSC we need a news 🗞️ update on clinical trial for this really pop.

0 · Reply

Beanie_Mojo Apr. 21 at 2:16 PM

$IPSC high $5 ....

1 · Reply

Market Cap	413.01M
Revenue (ttm)	109.16M
Net Income (ttm)	-9.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-8.78%
Debt to Equity Ratio	0.00

Volume	610,400
Avg Vol	1,283,106
Day's Range	N/A - N/A
Shares Out	180.35M
Stochastic %K	54%
Beta	1.55
Analysts	Strong Sell
Price Target	$4.40